The study evaluates the effectiveness of capecitabine in treating central nervous system (CNS) metastases in breast cancer patients, highlighting its role as a common treatment choice despite limited supporting data.
In a retrospective cohort of 209 patients, the researchers found a 3-month intracranial objective response rate (CNS-ORR) of 41.6% and a disease control rate (CNS-DCR) of 81.2%, with triple-negative breast cancer showing notably higher response rates.
However, the study reveals a poor overall prognosis for these patients, particularly for those with triple-negative breast cancer, who had shorter progression-free survival (PFS) and overall survival (OS) compared to
The study aimed to evaluate if reirradiation of recurrent glioblastoma with higher doses of hypofractionated stereotactic radiation therapy (HSRT) would improve patient outcomes compared to a lower dose while keeping side effects manageable.
A randomized trial involved 40 patients who were assigned to receive either 25 Gy in 5 fractions or 35 Gy in 5 fractions. Results showed no significant difference in progression-free survival (PFS) or overall survival (OS) between the two groups.
Despite a slight numerical increase in severe necrosis in the higher dose group, it was concluded that the lower dose (25 Gy/5 fx) should be the standard for HSRT due to similar effectiveness and potentially lower toxicity
- Recent advances in glioma diagnosis have been fueled by new technologies, enhancing our understanding of tumor behavior and leading to the updated 2021 WHO classification of CNS tumors.
- The article highlights key diagnostic methods like immunohistochemistry, genetic sequencing, and neuroimaging, which are essential for accurate glioma classification and treatment planning.
- It emphasizes the role of multidisciplinary collaboration and the potential of artificial intelligence and radiogenomics to improve glioma diagnosis and patient outcomes in the future.